Targeted multimodal liposomes for nano-delivery and imaging: An avenger for drug resistance and cancer

Current Gene Therapy

Volumn 13, Issue 5, 2013, Pages 322-334

  Gurudevan, Sneha ^a   Kanwar, Rupinder K ^a   Veedu, Rakesh N ^b   Sasidharan, Sreenivasan ^c   Kennedy, Richard L ^a   Walder, Ken ^a   Prasad, Neerati ^d   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

^d KAKATIYA UNIVERSITY   (India)

Author keywords

Immunoliposomes and gene transfer; Liposomes; Multidrug resistance

Indexed keywords

1, 2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ABRAXIS; ALZA; ANIONIC LIPOSOME; APOLIPOPROTEIN E; CURCUMIN; CYTARABINE; DAUNORUBICIN; DEPOCET; DEXAMETHASONE; DICLOFENAC; DIOLEOYLPHOSPHATIDYLCHOLINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; FLUOROURACIL; GEMLIP; GENE THERAPY AGENT; GILEAD; IMMUNOLIPOSOME; LIPOFECTAMINE; LIPOSOME; NAVELBINE; NITRIC OXIDE; OXALIPLATIN; PACLITAXEL; PEGYLATED LIPOSOME; RESVERATROL; RGD R9; SMALL INTERFERING RNA; TAT PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; COLORECTAL CARCINOMA; DRUG DELIVERY SYSTEM; ENCAPSULATION; HEMOPHILIA; HUMAN; HYPERTHERMIA; IMAGING; IMMUNITY; KAPOSI SARCOMA; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; LUNG CANCER; LUNG CARCINOMA; MENINGITIS; MULTIPLE MYELOMA; NANO DELIVERY SYSTEM; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVARY METASTASIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); SQUAMOUS CELL CARCINOMA; SUSTAINED DRUG RELEASE; UTERINE CERVIX CANCER;

ANIMALS; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LIPOSOMES; RNA, SMALL INTERFERING;

EID: 84890667377     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652321305131212123558     Document Type: Article

References (102)

1. Brown HA, Murphy RC. Working towards an exegesis for lipids in biology. Nat Chem Biol 2009; 5(9): 602-6.
2. Endo S, Escher BI, Goss K-U. Capacities of Membrane Lipids to Accumulate Neutral Organic Chemicals. Environ Sci Technol 2011; 45(14): 5912-21.
3. Palsdottir H, Hunte C. Lipids in membrane protein structures. Biochim Biophys Acta 2004; 1666(1-2): 2-18.
4. Koch A. Primeval cells: possible energy-generated and celldivision mechanisms. J Mol Evol 1984; 21(3):270-7.
5. Kuge O, Nishijimat M, Akamatsu Y. Phosphotidylserine biosynthesis in cultured Chinese hamster ovary cells. J Biol Chem 1986; 261(13): 5790-4.
6. Frezard F. Liposomes: from biophysics to the design of peptide vaccines. Braz J Med Biol Res 1999; 32: 181-9.
7. Schwendener RA, Ludewig B, Cerny A. Liposome-based vaccines. Biomed Life Sci 2010; 605: 163-75.
8. Yoshimoto M. Stabilisation of enzymes through encapsulation in liposomes. Methods Mol Biol. 2011; 679: 9-18.
9. Colletier J-P, Cahize B, Winterhalter M, Fournier D. Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol 2002; 2: 9.
10. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumours: challenges and solutions. Drug Discov Today 2003; 8(6): 259-66.
11. Krissansen GW, Kanwar JR. Treatment of demyelinating diseases. United States patent US20040053850 A1, 2007.
12. Kanwar JR, Mohan RR, Kanwar RK, Roy K, Bawa R. Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine 2010; 5(9): 1435-45.
13. Li F, Prevost S, Schweins R, et al. Small monodisperse unilamellar vesicles from binary copolymer mixtures. Royal Soc Chem 2009; 5: 4169-72.
14. Hope MJ, M.B. Bally, Mayer LD, Janoff AS, Cullis PR. Generation of multilamellar and unilamellar phospholipid vesicles. Chem Phys Lipids 1986; 40: 89-107.
15. Moon JJ, suh H, Bershteyn A, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011; 10: 243-51.
16. Kanwar Jr, Kanwar RK, Pandey S. Vascular attack by 5,6- Dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)- mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumours and multiple tumour foci. Cancer Res 2001; 61: 1948-56.
17. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91(10):4407-11.
18. Tiera MJ, Shi Q, Winnik FM, Fernandes JC. Polycation-based gene therapy: current knowledge and new perspectives. Curr Gene Ther 2011; 11(4):288-306.
19. Matoba T, Eqashira K. Anti-inflammatory gene therapy for cardiovascular disease. Curr Gene Ther 2011; 11(6): 442-6.
20. Mohr L, Yoon S-K, Simon J, et al. Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice. Hum Gene Ther 2001; 12(7):799-809.
21. Kaneda Y. Development of liposomes and pseudovirions with fusion activity for efficient gene delivery. Curr Gene Ther 2011; 11(6): 434-41.
22. Santos JL, Pandita D, Rodriques J, et al. Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration. Curr Gene Ther 2011; 11(1): 46-57.
23. Madeira C, Mendes RD, Ribeiro SC. et al. Non-viral delivery to mesenchymal stem cells using cationic liposomes for gene and cell therapy. J Biomed Biotechnol 2010; 735349: 12.
24. Bayart E, Cohen-Haquenauer O. Technological overview of iPS induction from human adult somatic cells. Curr Gene Ther 2013; 13(2): 73-92.
25. Takakuwa K, Fujita K, Kikuchi A, et al. Direct intratumoural gene transfer of the herpes simplex virus thymidine kinase gene with DNA liposome complexes: growth inhibition of tumours and lack of localization in normal tissues. Jpn J Cancer Res 1997; 88(2):166-75.
26. Uddin SN. Cationic lipids used in non viral gene delivery systems. Biotechnol Mol Biol Rev 2007; 2(3): 58-67.
27. Balazs DA, Godbey WT. Liposomes for use in gene delivery. J Drug Deliv 2010; 2011: doi:10.1155/2011/326597.
28. Farhood H, Serbina N, Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta 1995; 1235(2):289-295.
29. Gao X, Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 1996; 35:1027-36.
30. Liu F, Yang J, Huang L, Liu D. New cationic lipid formulations for gene transfer. Pharmaceut Res 1996; 12(12):1856-60.
31. Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL. Brain delivery of proteins by the intranasal route of administration: A comparison of cationic liposomes versus aqueous solution formulations. J Pharmaceut Sci 2009; 99(4):1745-61.
32. Filion MC, Philips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1997;1329:345-56.
33. Patil SD, Rhodes DG, Burgess DJ. Anionic liposomal delivery system for DNA transfection. APPS J 2004; 6(4):e29.
34. Marty R, N'soukpoé-Kossi CN, Charbonneau D, Weinert CM, Kreplak L, Tajmir-Riahi H-A. Structural analysis of DNA complexation with cationic lipids. Nucleic Acids Res 2009; 37(3):849-57.
35. Zuidam NJ, Barenholz Y. Characterization of DNA-lipid complexes commonly used for gene delivery. Int J Pharmaceut 1999; 183(1):43-6.
36. Lasic DD. The mechanism of vesicle formation. Biochem J 1998; 256:1-11.
37. Wang D, Kong L, Wang J, He X, Li X, Xiao Y. Polymyxin E Sulfate- Loaded Liposome for Intravenous Use: Preparation, Lyophilization, and Toxicity Assessment In Vivo. PDA J Pharm Sci Tech 2009; 63(2):159-67.
38. Wagner A, Vorauer-Uhl K, Katinger H. Liposomes produced in a pilot scale: production, purification and efficiency aspects. Eur J Pharm Biopharm 2002; 54(2):213-9.
39. Abraham SA, Edwards K, Karlsson G, et al. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 2002; 1565(1):41-54.
40. Ishida T, Takanashi Y, Doi H, Yamamoto I, Kiwada H. Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes. Int J Pharmaceut 2002; 232(1-2): 59-67.
41. Liu J-J, Hong R-L, Cheng W-F, Hong K, Chang F-H, Tseng Y-L. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Anticancer Drugs 2002; 13(7): 709-17.
42. Nii T, Ishii F. Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. Int J Pharmaceut 2005; 298(1): 198-205.
43. Zhigaltsev IV, Maurer N, Akhong Q-F, et al. Liposomeencapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention. J Control Release 2005; 104(1): 103-11.
44. Szebeni J, Bedocs P, Rozsnyay Z, et al. Liposome-Induced Complement Activation and Related Cardiopulmonary Distress in Pigs: Factors Promoting Reactogenicity of Doxil and Ambisome. Nanomedicine 2012; 8(2): 176-84.
45. Du H, Cui C, Wang L, Liu H, Cui G. Novel Tetrapeptide, RGDF, Mediated Tumour Specific Liposomal Doxorubicin (DOX) Preparations. Mol Pharmaceut 2011; 8(4): 1224-32.
46. Wu C, Yu C, Chu M. A gold nanoshell with a silica inner shell synthesized using liposome templates for doxorubicin loading and near-infrared photothermal therapy. Int J Nanomedicine 2011; 6:807-13.
47. Dell'olio M, Potito scalzulli R, Sanpaolo G, et al. Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2011; 52(7):1222-9.
48. Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A Randomized Controlled Trial Comparing Intrathecal Sustained-release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients with Neoplastic Meningitis from Solid Tumours. Clin Cancer Res 1999; 5(11):3394-402.
49. Piccaluga PP, Visani G, Martinelli G, et al. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia. Leukemia 2002; 16(9):1880-1.
50. Yang F, Jin C, Jiang Y, et al. Liposome based delivery systems in pancreatic cancer treatment: From bench to bedside. Cancer Treat Rev 2011; 37(8): 633-42.
51. Graeser R, Bornmann C, Esser N, et al. Antimetastatic effects of liposomal Gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer. Pancreas 2009; 38(3):330-7.
52. Vishnu P, Roy V. Safety and efficacy of nab-Paclitaxel in the treatment of patients with breast cancer. Breast Cancer 2011; 5:53-65.
53. Patel NR, Rathi A, Mongayt D, Torchilin VP. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm 2011; 416(1): 296-9.
54. Zhang H, Wang Z-y, Gong W, Li Z-p, Mei X-g, Lv W-l. Development and characteristics of temperature-sensitive liposomes for vinorelbine bitartrate. Int J Pharm 2011; 414(1-2): 56-62.
55. Lin Y-L, Liu Y-K, Tsai NM, et al. A Lipo-PEG-PEI Complex for Encapsulating Curcumin that Enhances its Antitumour Effects on Curcumin-sensitive and Curcumin-resistance Cells. Nanomedicine 2012; 8(3): 318-27.
56. Wang X-X, Li Y-B, Yao H-J, et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011; 32(24): 5673-87.
57. Yang C, Liu H, Fu Z, Lu W. Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma. BMC Biotechnol 2011; 11(1): 21.
58. Park JW, Benz CC, Martin FJ. Future directions of liposome-and immunoliposome-based cancer therapeutics. Semin Oncol 2004; 32(6): 196-205.
59. Ishida T, Harashima H, Kiwada H. Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors. Curr Drug Metab 2001; 2(4): 379-409.
60. Harrington KJ, Rowlinson-Busza G, Syringos LN, et al. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumour xenograft model. Clinical Cancer Research 2000; 6: 4939.
61. Stover T, Kester M. Liposomal delivery enhances short-chain ceramide- induced apoptosis of breast cancer cells. J Pharmacol Exp Ther 2003; 307(2): 468-75.
62. Thigpen JT, Aghajanian CA, Alberts DS, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005; 96(1): 10-8.
63. Martín M, Sánchez-Rovira P, Muñoz M, et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol 2011; 22(12): 2591-6.
64. Yatuv R, Robinson M, Dayan-Tarshish I, Baru M. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. Int J Nanomedicine 2010; 5: 581-91.
65. Sawant RR, Torchilin VP. Liposomes as 'smart' pharmaceutical nanocarriers. Soft Matter 2010; 6(17): 4026-44.
66. Pollock S, Antrobus R, Newton L, et al. Uptake and trafficking of liposomes to the endoplasmic reticulum. FASEB J 2010; 24(6): 1866-78.
67. Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. pH sensitive liposomes: possible clinical implications. Science 1980; 210 (4475):1253-5.
68. Provoda CJ, Stier EM, Lee K-D. Tumour Cell Killing Enabled by Listeriolysin O-liposome-mediated Delivery of the Protein Toxin Gelonin. J Biol Chem 2003; 278(37): 35102-8.
69. Ta T, Convertine AJ, Reyes CR, Stayton PS, Porter TM. Thermosensitive Liposomes Modified with Poly(Nisopropylacrylamide- co-propylacrylic acid) Copolymers for Triggered Release of Doxorubicin. Biomacromolecules 2010; 11(8): 1915-20.
70. Koning G, Eggermont A, Lindner L, ten Hagen T. Hyperthermia and Thermosensitive Liposomes for Improved Delivery of Chemotherapeutic Drugs to Solid Tumours. Pharmaceut Res 2010; 27(8): 1750-4.
71. Chen Q, Tong S, Dewhirst MW, Yuan F. Targeting tumour microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther 2004; 3(10): 1311-7.
72. Tai L-A, Tsai P-J, Wang Y-C, Wang Y-J, Lo L-W, Yang C-S. Thermosensitive liposomes entrapping iron oxide nanoparticles for controllable drug release. Nanotechnology 2009; 20(13):135101.
73. Lee S, Shim G, Kim S, et al. Enhanced transfection rates of small - interfering RNA using dioleylglutamide-based magnetic lipoplexes. Nucl Acid Ther 2011; 21(3): 165-72.
74. Namgung R, Singha K, Yu MK, et al. Hybrid superparamagnetic iron oxide nanoparticle-branched polyethylenimine magnetoplexes for gene transfection of vascular endothelial cells. Biomaterials 2010; 31(14): 4204-13.
75. Siwak DR, Tari AM, Lopez-Berestein G. The potential of drugcarrying immunoliposomes as anticancer agents: commentary re: J. W. Park et al., Anti-HER2immunoliposomes: enhanced efficacy due to targeted delivery. Clin Cancer Res 2002; 8: 1172-1181.
76. Almenar-Queralt A, Duperray A, Miles L, Felez J, Altieri D. Apical topography and modulation of ICAM-1 expression on activated endothelium. Am J Pathol 1995; 147(5): 1278-88.
77. Kanwar J, Berg R, Lehnert K, Krissansen G. Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumour immunity. Gene Ther 1999; 6(11): 1835-44.
78. Kanwar JR, Berg RW, Yang Y, et al. Requirements for ICAM-1 immunogene therapy of lymphoma. Cancer Gene Ther 2003; 10(6): 468-76.
79. Hua S, Chang H-I, Davies NM, Cabot PJ. Targeting of ICAM-1- directed immunoliposomes specifically to activated endothelial cells with low cellular uptake: use of an optimized procedure for the coupling of low concentrations of antibody to liposomes. J Liposome Res 2011; 21(2): 95-105.
80. Murciano J-C, Muro S, Koniaris L, et al. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 2003; 101(10): 3977-84.
81. Gosk S, Moos T, Gottstein C, Bendas G. VCAM-1 directed immunoliposomes selectively target tumour vasculature in vivo. Biochim Biophys Acta 2008; 1778(4): 854-63.
82. Hertlein E, Triantafillou G, Sass EJ, et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010; 116(14): 2554-8
83. Tata P. Evaluation of MUC4 glycoprotein as a potential target for immunoliposomes in the treatment of pancreatic adenocarcinoma. Pharmaceutical Science Master's Thesis. North-eastern University 2008.
84. Guin S, Ma Q, Padhye S, Zhou Y-Q, Yao H-P, Wang M-H. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. Cancer Chemother Pharmacol 2011; 67(5): 1073-83.
85. Kanwar JR, Singh N, Kanwar RK. Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. Nanomedicine 2011; 6(4): 701-14.
86. Riganti C, Voena C, Kopecka J, et al. Liposome-Encapsulated Doxorubicin Reverses Drug Resistance by Inhibiting PGlycoprotein in Human Cancer Cells. Mol Pharm 2011; 8(3): 683-700.
87. Kopecka J, Campia I, Olivero P, et al. A LDL-masked liposomaldoxorubicin reverses drug resistance in human cancer cells. J Control Release 2011; 149(2): 196-205.
88. Cheng SH, Yew NS, Ziegler RJ. Compositions and methods for treating lysosomal disorders. European Patent EP2147681 A1, 2009 Oct 29.
89. Michieli M, Damiani D, Ermacora A, et al. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Brit J Haematol 1999; 106(1):92-9.
90. Jiang J, Yang S-J, Wang J-C, et al. Sequential treatment of drugresistant tumours with RGD-modified liposomes containing siRNA or doxorubicin. Eur J Pharm Biopharm 2010; 76(2): 170-8.
91. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in Pglycoprotein- mediated drug resistant tumour cells. Int J Pharm 2007; 329(1-2): 94-102.
92. Yin Y, Chen D, Qiao M, Wei X, Hu H. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: Ex vivo bioadhesion and in vivo biodistribution. J Control Release 2007; 123(1): 27-38.
93. Pinzón-Daza ML, Garzón R, Couraud PO, et al. The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells. Brit J Pharmacol 2012; 167(7): 1431-7.
94. Mohanty C, Das M, Kanwar JR, Sahoo SK. Receptor mediated tumour targeting: an emerging approach for cancer therapy. Curr Drug Deliv 2011; 8(1): 45-58.
95. Kanwar RK, Kanwar JR. Unpublished work. 2013.
96. Kanwar JR, Gurudevan S, Kanwar RK. The utilisation of toll like receptors and their adaptors in adjuvant immunotherapy for cancer. In communication. 2013.
97. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW. Mouse B7-H3 induces antitumour immunity. Gene Ther 2003; 10(20): 1728-34.
98. Kanwar JR, Kanwar RK, Pandey S, Ching L-M, Krissansen GW. Vascular Attack by 5,6-Dimethylxanthenone-4-acetic Acid Combined with B7.1 (CD80)-mediated Immunotherapy Overcomes Immune Resistance and Leads to the Eradication of Large Tumours and Multiple Tumour Foci. Cancer Res 2001; 61(5): 1948-56.
99. Kanwar JR, Shen W-P, Kanwar RK, Berg RW, Krissansen GW. Effects of Survivin Antagonists on Growth of Established Tumours and B7-1 Immunogene Therapy. J Natl Cancer I 2001; 93(20): 1541-52.
100. Taneichi M, Tanaka Y, Kakiuchi T, Uchida T. Liposome-coupled peptides induce long-lived memory CD8 T cells without CD4 T cells. PLoS ONE 2010; 5(11): e15091.
101. van Rooijen N, van Kesteren-Hendrikx E. Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res 2002; 12(1-2): 81-94.
102. Fukushima A, Ozaki A, Ishida W, et al. Suppression of macrophage infiltration into the conjunctiva by clodronate liposomes in experimental immune-mediated blepharoconjunctivitis. Cell Biol Int 2005; 29: 277-86.